Ipsen’s collaboration with Exelixis is on track to file cancer treatment, Cabometyx, for a new liver cancer indication in the first half of next year, following positive Phase III trial results. The randomised, double-blind CELESTIAL study was set up to test Cabometyx in 760 patients who have advanced hepatocellular carcinoma (HCC), which is the sixth
Kite Pharma has submitted the first CAR-T cell therapy in Europe, with the aim of gaining permission to market its axicabtagene ciloleucel to treat patients with three subtypes of aggressive non-Hodgkin lymphoma (NHL). CAR-T is a new treatment approach that it is specifically manufactured for each individual patient, allowing for a more personalised and effective
An experimental therapy for bladder cancer is predicted to soon be entering Phase I clinical trials in the UK following a development pact signed between Cancer Research UK, its commercial arm Cancer Research Technology, and Sitka Biopharma, a Canadian biotech. Sitka’s therapy (STK-01) is being developed to improve delivery of chemotherapy in non-muscle invasive bladder
The research team from University of Salford have recently identified a key protein which is believed to be a leading causes of resistance tamoxifen, a commonly used drug cancer. Throughout patient treatment, around half of those are administered tamoxifen, a treatment which blocks oestrogen receptors as part of its mechanism of action. Although the cancer
Cancer Research UK have funded a trial that allows GP surgeries to test for Barrett’s Oesophagus, a condition which can increase the chances of developing oesophageal cancer. Up to 150 GP practices nationwide will trial offering the Cytosponge test, a less invasive way to test for changing oesophageal cells in patients experiencing acid reflux symptoms.
AZ announce data that it says will establish its lung cancer drug Tagrisso as standard second line treatment in patients with certain mutations. The data showed Tagrisso slowed tumour progression compared with standard chemotherapy and was also more effective in patients with brain metastases. Tagrisso is approved in second line non-small cell lung cancer with
Bristol-Myers Squibb Company and Nektar Therapeutics have announced a new clinical collaboration to evaluate combining Bristol-Myers Squibb’s Opdivo with Nektar’s investigational medicine, NKTR-214, as a potential treatment regimen in five different tumour types and seven potential indications. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. Whilst NKTR-214 is an investigational immuno-stimulatory
Celgene and Jounce Therapeutics are to join in a global strategic collaboration with the aim of developing and commercialising immuno-oncology treatments. The collaboration will provide Celgene the options to jointly develop and commercialise Jounce’s primary product candidate, JTX-2011, and other innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages.
Cancer Research UK’s Centre for Drug Development (CDD), in partnership with Amgen, have launched a new clinical trial to test a drug with the aim to stop a patient’s immune system from protecting tumours.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney. Currently kidney cancer is known to be resistant against chemotherapy and radiation. About 61,000 new cases of kidney cancer are diagnosed each year,